Potential conflict of interest: Yao-Chun Hsu reports having received lecture fees from the Merck Sharp & Dohme (Taiwan) and the Roche company (Taiwan). There is no other conflict of interest to declare.
Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients
Version of Record online: 18 FEB 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 59, Issue 4, pages 1293–1302, April 2014
How to Cite
Hsu, Y.-C., Lin, J.-T., Ho, H. J., Kao, Y.-H., Huang, Y.-T., Hsiao, N.-W., Wu, M.-S., Liu, Y.-Y. and Wu, C.-Y. (2014), Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology, 59: 1293–1302. doi: 10.1002/hep.26892
- Issue online: 24 MAR 2014
- Version of Record online: 18 FEB 2014
- Accepted manuscript online: 12 OCT 2013 09:51AM EST
- Manuscript Accepted: 8 OCT 2013
- Manuscript Revised: 23 SEP 2013
- Manuscript Received: 25 MAY 2013
- Supported in part by Taiwan's National Health Research Institutes (PH-100-PP-54, PH-101-PP-23) and Taiwan's National Science Council (NSC 101-2314-B-650-003)
Additional Supporting Information may be found in the online version of this article at Wiley Online Library.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.